1 October 2015 - A group of patients and campaigners has called on Britain's health minister to over-ride patents protecting Roche's expensive breast cancer drug Kadcyla to allow for the import or manufacture of cut-price copies.

The move shows the growing pricing pressure on drug companies on both sides of the Atlantic, especially in the field of cancer where new treatments can cost well over $100,000.

In a letter to Health Secretary Jeremy Hunt on Thursday, the Coalition for Affordable T-DM1 said the government should grant a compulsory licence for patents covering Kadcyla, or T-DM1, allowing other companies to supply so-called biosimilar versions.

For more details, go to: http://www.reuters.com/article/2015/10/01/roche-cancer-britain-idUSL5N1211VA20151001?rpc=401